Table 5 Uro-oncological studies registered in ClinicalTrials.gov
Total | Randomized studies | Recruiting | Active, not recruiting | Not yet recruiting | Enrolling by invitation | Completed | Suspended | Terminated | Withdrawn | Others* | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | 1413 | 469 | 536 | 300 | 23 | 20 | 399 | 11 | 99 | 23 | 2 |
(33.2%) | (37.9%) | (21.2%) | (1.6%) | (1.4%) | (28.2%) | (0.8%) | (7%) | (1.6%) | (0.1%) | ||
Kidney neoplasms | 1251 | 385 | 518 | 247 | 26 | 15 | 317 | 12 | 86 | 27 | 3 |
(30.8%) | (41.4%) | (19.7%) | (2.1%) | (1.2%) | (25.3%) | (1.0%) | (6.9%) | (2.2%) | (0.2%) | ||
Urinary bladder neoplasms | 354 | 98 | 159 | 63 | 5 | 6 | 89 | 0 | 23 | 9 | 0 |
(27.7%) | (44.9%) | (17.8%) | (1.4%) | (1.7%) | (25.1%) | (0%) | (6.5%) | (2.5%) | (0%) | ||
Testicular neoplasms | 96 | 19 | 46 | 22 | 1 | 0 | 19 | 1 | 4 | 3 | 0 |
(19.8%) | (47.9%) | (22.9%) | (1%) | (0%) | (19.8%) | (1%) | (4.2%) | (3.1%) | (0%) |